C arotid endarterectomy (CEA) has been demonstrated to be of value for select patients with carotid stenosis. Over the past decade, the utilization of carotid artery stenting (CAS), as an alternative to CEA has increased. 1 Racial and ethnic disparities as seen in the access to and utilization of other newer treatment modalities might also be present in the utilization of CAS. 2 In fact studies have shown that white males are more likely to undergo percutaneous or surgical treatment for peripheral arterial and carotid disease when compared with females or individuals from other races. 3 Although some studies have identified disparate patterns of utilization of carotid imaging and surgical revascularization between patients from different racial or ethnic backgrounds, [3] [4] [5] [6] other studies have not confirmed these findings. 7 The studies that did demonstrate racial differences also found higher mortality rates after CEA in blacks and Hispanics; 4, [8] [9] [10] [11] [12] and some studies showed a relative increase in the incidence of postprocedural stroke and myocardial infarction (MI) in blacks after CEA. 9, 13 In a recent study analyzing a nationwide inpatient sample (NIS) from 2005 to 2008, postprocedural mortality was significantly higher in Hispanic and blacks than in whites after CEA but not after CAS. In addition, postprocedural stroke occurred more frequently in blacks than in whites or Hispanics after both CEA and CAS. 14 The racial and ethnic basis for discrepant
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resource utilization and outcomes is likely multifactorial and may be related to socioeconomic status, difference in cultural belief, and lack of access to health care. [7] [8] [9] [10] [11] Although these studies identify differences in postprocedural outcomes related to race and ethnicity, they do not provide information about other racial groups, such as Asians and American Indians. In addition, these studies do not provide important information on medication use, carotid lesion anatomic factors, or recurrent stenosis, which are factors known to have significant impact on clinical outcomes after carotid revascularization. Finally, these studies focus on in-hospital outcomes only. Critically relevant postdischarge adverse events, including stroke, MI, or death, are not captured in these inpatient assessments.
We hypothesize that significant racial and ethnic variation exists in the utilization, management and outcomes associated with carotid artery revascularization procedures. In our CARE registry-based study, we analyzed demographic, clinical and angiographic factors, in-hospital outcomes, and 30-day postprocedural outcomes.
Methods
Registry
CARE Registry is an initiative of the American College of Cardiology Foundation, the Society for Cardiovascular Angiography and Interventions, the Society of Interventional Radiology, the American Academy of Neurology, the American Association of Neurological Surgeons/Congress of Neurological Surgeons, the Society for Vascular Medicine, and the Society of Vascular and Interventional Neurology. 15 The CARE Registry is a comprehensive national registry of patients undergoing both CAS and CEA. Patients aged >18 undergoing CAS or CEA at participating institutions are included in the Registry. Standard data definitions and collection protocols, a data dictionary, and uniform data collection tools have been developed and are posted at the National Cardiovascular Data Registry (NCDR) web site: http://www.ncdr.com/webncdr/common/. As of November 2012, the Registry included data from 14 343 CAS procedures and 11 099 CEA procedures performed at 171 sites in the United States.
Patients
Men and women aged ≥18 years who underwent CAS and CEA between January 2007 and December 2012 for symptomatic or asymptomatic carotid stenosis were included. To assess the utilization of the 2 modalities of carotid revascularization over a period of time, we chose 3 consecutive 2-year blocks were excluded because of small numbers. Exclusion criteria included patients with nonatherosclerotic carotid artery disease (spontaneous carotid artery dissection and fibromuscular dysplasia), patients who had general anesthesia for CAS, patients with acute evolving stroke, and patient with missing information about race or ethnicity.
Race
For the purpose of this study, racial and ethnic groups were consolidated into the following 4 categories-non-Hispanic whites, Hispanic, black, and other groups (OG-including American Indians and Asians).
Definitions
All study definitions were derived from the CARE Registry data dictionary-elements and definitions v1.08. In-hospital adverse events (defined individually below) included new events occurring during or after the procedure but before discharge. In-hospital mortality was defined as death occurring during the procedure or before hospital discharge. Acute MI was defined as a rise and fall of cardiac biomarkers with at least 1 of the values above normal for the hospital's laboratory (above the 99th percentile of the upper reference limit [URL]) together with evidence of myocardial ischemia defined as at least 1 of these following: ischemic symptoms; ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block), development of pathological Q waves in the ECG; imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Hemorrhagic complications included procedure-related bleeding or hematoma requiring red blood cell transfusion (primary outcome) and intracerebral hemorrhage. Transient ischemic attack was defined as a focal neurological abnormality of sudden onset, lasting <24 hours, and presumed to be ischemic in origin. Ischemic stroke was defined as focal neurological abnormality resulting in residual symptoms lasting >24 hours and leading to impaired functional outcomes.
Outcomes
The primary study outcome was change in the proportional utilization of carotid revascularization modality (CEA versus CAS) by different racial and ethnic groups from 2007 to 2012. Secondary outcomes included racial and ethnic variation in medications prescribed on discharge, and in-hospital and 30-day outcome (major adverse cardiac and cerebrovascular events [MACCE] and all cause readmissions) of the patients undergoing carotid revascularization.
Statistical Analysis
Categorical variables will be presented as frequencies and percentages and unadjusted comparisons will be performed using χ 2 or Fisher exact tests where appropriate. Continuous variables will be presented as mean±SD (median with interquartile range where non-normally distributed) and unadjusted comparisons will be made using ANOVA and Mann-Whitney test where appropriate. Hierarchical adjusted logistic regression was used to produce odds ratios (ORs) and 95% confidence intervals. In-hospital and 30-day events were calculated after adjusting the data for variables most likely to confound postprocedural outcomes after carotid revascularization, including age, sex, atrial fibrillation/flutter, prior CEA or CAS, neurological events before the procedure (symptomatic status), preprocedural aspirin or thienopyridine use, and discharge medications, including aspirin, thienopyridine, and statins. Clinical variables known to associate with a particular race (diabetes mellitus in Hispanics and hypertension in blacks) were not adjusted because the process could attenuate the impact of race on outcomes. These models were additionally clustered by site, in which they were entered in the model as a random effect. Statistical significance was defined as P<0.05. For evaluating trends in use of carotid revascularization modality, we used the Cochran-Armitage trend test of proportions of CEA/CAS over time. All statistical analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC).
Results
A total of 13 129 eligible CAS procedures were identified between May 2005 and December 2012. The racial distribution within the CAS population was as follows: non-Hispanic whites, 89.3%; blacks, 4.4%; Hispanics, 4.3%; and other racial groups (OG), 2.0%. On the surgical front, a total of 10 953 eligible CEA procedures were identified during the same time period. The racial distribution within the CEA population was as follows: non-Hispanic whites, 92.6%; blacks, 3.5%; Hispanics, 2.8%; and OG, 1.1%. Demographic and clinical variables among various racial groups undergoing carotid revascularization are summarized in Tables 1 and  2 . Twenty-one patients (<0.001%) were excluded because of missing race/ethnicity data. Figure 1 shows the trends in proportional utilization of carotid revascularization modalities by race from 2007 to 2012. Our study shows that there has been a significant increase in the proportionate utilization of CAS in non-Hispanic whites and OG, whereas CEA utilization showed a proportionate increase among blacks and Hispanics ( Figure 1 ). When hospitals performing both CAS and CEA were exclusively analyzed (sites, 53; CEA, 10 409; CAS, 4881), a similar trend persisted except that the trend was not statistically significant in blacks ( Figure  I in the online-only Data Supplement). Characteristics of hospitals where patients sought care for CAS and CEA are listed in Tables I and II in the online-only Data Supplement. As expected, the black and Hispanic races were more common in the Southern region.
Trends in Utilization of CAS Versus CEA Within Various Racial Groups
Postprocedure Medication Prescription
Prescription of postprocedural aspirin and clopidogrel was >90% and that of statin was ≈80% among patients undergoing CAS, without a difference between races. After CEA, however, prescription of aspirin was <90% with a significantly lower rate of prescription for black and Hispanic races compared with white and other groups (P<0.05). Prescription of statins post CEA was significantly lower for non-Hispanic whites and blacks races compared with Hispanics and other groups (P=0.04; Figure 2 ).
In-Hospital Outcomes
Adjusted in-hospital outcomes (death, stroke, MI, and combined MACCE) for any carotid revascularization (CAS or CEA) remained similar within different racial groups during the period of 2007 to 2012 (Tables 3-5 ). Incidence of in-hospital death and MI was similar among racial groups regardless of carotid revascularization strategy (P=0.37 for death and P=0.85 for MI). Although incidence of in-hospital stroke after CAS did not differ between racial groups, the rate after CEA trended higher among blacks and OG compared with non-Hispanic whites and Hispanic groups, but did not reach statistical significance (P=0.06). 
Discussion
In this large, multicenter, multidisciplinary national registry of patients who underwent carotid revascularization from 2007 to 2012, there has been a significant shift from CEA toward CAS in non-Hispanic whites and OG but from CAS to CEA for blacks and Hispanic populations. Although in-hospital outcomes for CAS and CEA were similar across racial and ethnic groups, 30-day stroke and MACCE were not. At 30-day follow-up, the risk of stroke or MACCE was no different across groups after CAS but was significantly higher for the black population after CEA, a risk that was also substantially higher than that observed for black after CAS.
Utilization Trends
Our analysis identified that carotid revascularization techniques were predominantly used in non-Hispanic white patients: 89.3% of those undergoing CAS and 92.6% of those undergoing CEA were non-Hispanic whites. As a perspective, according to the US Census Bureau statistics, non-Hispanic white race is estimated to comprise 63% of the total population, whereas Hispanics (16.9%) and blacks (13.1%) are the 2 largest minority groups. 16 Although the randomized trials comparing CEA versus CAS have engendered some controversy about the impact of patient selection and operator experience on clinical outcomes, these studies have had significant impact on practice and utilization trends in the field of carotid revascularization. A NIS 17 evaluating carotid revascularization trends from 1998 to 2008 showed doubling of proportional utilization of CAS in 2005-a possible impact of the pro-CAS results from the SAPPHIRE trial. 18 Subsequently, utilization declined slightly after the release of SPACE and EVA-3S trial results. 19, 20 Our study demonstrates that, after a drop in utilization following SPACE and EVA-3S, the release of the CREST trial data may have led to an increased utilization of CAS from 2007 to 2012, 1 although utilization significantly differed between patients from different racial groups. While the increased utilization of CAS in non-Hispanic whites and OG paralleled the national trend from 2007 to 2012, an opposite trend was noted in Hispanics and blacks, despite a higher incidence of significant heart disease (>2 vessel coronary artery disease, left main coronary artery disease >50%, New York Heart Association III/IV congestive heart failure, high-grade CCS III/IV angina, LVEF<0.30, MI within 6 weeks). The reasons for these contrasting trends are likely multifactorial. First, patient economic, demographic, or geographic disparity may 
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June 2015 affect access to health care; associated referral patterns may determine if a patient is referred to a hospitals with surgical specialists (favoring CEA) or interventional vascular specialists (favoring CAS). Only 31% (53 of 171) of the sites evaluated in our NCDR-CARE-based analysis report both CEA and CAS. In addition, the outcomes after 1 mode of carotid revascularization could be more robust when compared with the other, which ultimately could lead to institution-specific referral patterns. Second, the reimbursement for CAS by Centers for Medicare and Medicaid services (CMS) and to a variable extent by other payers has been dependent on patients meeting certain high-risk criteria potentially associated with a higher incidence of adverse outcomes after CEA. This difference in utilization of carotid revascularization technique could represent a surrogate marker of difference in insurance status among the study racial groups. Our study showed a significantly higher incidence of uninsured blacks and Hispanic patients (compared with non-Hispanic whites) within the CAS cohort; however, this difference was not present in the CEA cohort. This discrepancy in insurance status was also observed with a NIS by Schneider et al 14 where it was shown that black patients were more likely to have Medicare or private insurance. Another reason for lower utilization of carotid revascularization among minorities when compared with non-Hispanic whites is a potential referral bias. Minorities are less likely to be screened for asymptomatic carotid disease, when compared with non-Hispanic white patients, 21 and are more likely to present with advanced and symptomatic atherosclerotic arterial disease. Third, cultural beliefs within a particular race may represent a barrier against acceptance of a newer modality of treatment (CAS) compared with the traditional one (CEA) or vice versa. 22 Furthermore, the institutions within the NCDR, although comprehensive, are not an absolute representation of nationwide practice, and as seen from the size of the non-Hispanic whites cohort, the other racial groups may be heavily under-represented in this study. Finally, although not systematically captured in the CARE registry, operator experience is critical in outcomes of patients undergoing carotid revascularization procedures. To ensure operator competence, a lead-in study was completed before operators were included in the CREST trial. 23 In addition to the minimum experience in performing CAS, this study ensured a low complication rate, use of proper stenting technique discouraging use of erroneous techniques, such as use of general anesthesia. Similarly, use of proper surgical technique and anesthesia should be considered during CEA, because although overall cardiovascular outcomes may not be different, patients who undergo regional anesthesia have shorter operative and anesthesia times compared with general anesthesia.
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Postprocedure Discharge Medications
Unlike patients undergoing CAS, those undergoing CEA had significant racial differences with regard to aspirin and statin prescription at discharge. After CEA, blacks had the lowest use of aspirin and statins compared with other racial groups. Such disparities in aspirin use for secondary prevention have been elucidated in several studies. Brown et al analyzed this from the 2001 Behavioral Risk Factor Surveillance System, and found that in patients with cardiovascular disease, blacks (OR, 0.5) and Hispanics (OR, 0.7) were less likely to receive aspirin therapy for secondary prevention. 25 These differences were found to be unrelated to differences in sociodemographic and cardiovascular risk factors. Similarly, an analysis of the Get with the Guidelines-Coronary Artery Disease (GWTG-CAD) program between January 2002 and June 2007 found that post MI, black patients had significantly lower use of aspirin at discharge and were less likely to receive guidelinedirected medical therapy. 26 Similar observations were noted with regards to lipid lowering therapies (at discharge) within the National Registry of Myocardial Infarction database. 27 In our study, however, a racial discrepancy in discharge medications was seen after CEA but not after CAS. The reason for this difference is difficult to ascertain especially because health insurance status was similar between races within the CEA cohort. However, it could reflect a relative lack of implementation of performance measures after CEA, and indicates a need to reinforce guideline-directed therapy after surgical carotid revascularization to ensure minimization of disparities in care. Recent emphasis on improving quality and access to care, establishment and maintenance of performance measures, represent avenues where utilization of the large NCDR-based contemporary data (2007-2012) could aid future planning. Values are expressed as %. CAS indicates carotid artery stenting; MI, myocardial infarction; and MACCE, major adverse cardiac and cerebrovascular events.
*Adjusted P value: adjusted for the following variables-age, gender, atrial fibrillation/flutter, prior CEA or CAS, neurological events before the procedure (symptomatic status), preprocedural aspirin or thienopyridine use, and discharge medications including aspirin, thienopyridine, and statins. 14 CAS data showed a similar trend with blacks having the highest periprocedural stroke (3.1% versus 1.5% in Hispanics and non-Hispanic whites; P<0.05) and MI (0.5% versus 0.4% in Hispanics and <0.1% in non-Hispanic whites, P<0.05) compared with other groups, whereas no difference was noted among racial groups with regards to periprocedural mortality. 14 Our study did not demonstrate any difference in postprocedural in-hospital outcomes after in either mode of carotid revascularization. This may be because of couple of reasons. First, the volume of patients within the NCDR database is considerably lower than that of the NIS and may therefore have failed to show any difference between races. Second, our study deals with a more contemporary time period in which advances in surgical and interventional techniques and establishment of quality and performance measures may have attenuated the impact of race on outcomes.
30-Day Outcomes
Data on the impact of racial differences on 30-day outcomes after carotid revascularization are currently lacking. Our study represents the first effort to explore this subject. Although the follow-up of patients post index revascularization was 78% to 80%, it is noteworthy that all outcome measures were similar between racial groups at 30 days post CAS. After CEA, however, patients in the blacks group had a significantly higher rate of stroke and MACCE (Table 3 -5) compared with other groups at 30 days (P<0.05). This finding may be attributed to several factors. First, the blacks within CEA cohort had significantly higher proportion of hypertensive patients compared with other races-a variable known to confer higher risk of stroke and MACCE. [28] [29] [30] Second, although the pre/post procedure medications were adjusted in the outcomes model, the prescription of aspirin and statins to the CEA cohort in our study was significantly lower when compared with other races. Lipid-lowering therapy has been shown to confer short-and long-term benefit after cardiovascular and cerebrovascular procedures for atherosclerotic disease. [31] [32] [33] [34] [35] Patients in the blacks group also had a higher incidence of stroke post CEA. Whether the higher incidence of stroke in black patients is related to a lower prescription of aspirin and statins or not, cannot be analyzed by our study. Nevertheless, prescription of these guideline-directed medications should be ensured in black patients in particular, to eliminate racial disparity and improve outcomes. Finally, among the CEA cohort, the black population had a higher proportion of patients with American Society of Anesthesiologists (ASA) grade 3 or 4 compared with other groups thereby indicating an inherently more vulnerable subset potentially predisposed to worse 30-day outcomes compared with other groups.
Limitations
We cannot rule out the potential for residual unmeasured confounding or uncontrolled selection bias, despite our employment of an adjusted model for outcome analysis. Furthermore, although there is standardization and uniformity in CARE Registry data collection, quality control, and participant feedback, any large national database effort is inherently imperfect. Lack of adjudicated outcomes, prespecified end points, and lack of an angiographic core laboratory are significant limitations. Patient-based and institutional factors used to decide the mode of carotid revascularization (CAS or CEA) are not available. Although 30-day outcome data were not available for all patients in our study, the rate of incomplete outcome ascertainment was uniform across treatment groups; this loss to follow-up may have led to less precise estimates of 30-day ischemic event rates, but would not have affected our primary outcome, namely utilization rates of carotid revascularization modality by race. Finally, data on operator experience in CAS, which might influence both ischemic and hemorrhagic procedural risk, is unavailable in the CARE Registry.
Conclusions
During the study period, utilization of CAS and CEA was highest in non-Hispanic white population. There was a trend toward increased CAS utilization over time among non-Hispanic whites and OG, and a trend toward increased CEA utilization among Hispanics and blacks. Postprocedural aspirin and statin prescription was similar across all racial groups within the CAS cohort but was found to be disparate among the CEA cohort, with blacks having the lowest prescription rates. In-hospital MACCE remained comparable between groups, whereas 30-day MACCE was significantly higher in blacks. 
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